NeuroOne Medical Technologies Corporation has announced that it received a notification from the Nasdaq Stock Market indicating a failure to meet the minimum bid price requirement for continued listing. The company's common stock has had a closing bid price below $1.00 per share for 30 consecutive business days, prompting the notice. According to Nasdaq rules, the company has 180 calendar days, until November 3, 2025, to regain compliance by ensuring its stock price closes at or above $1.00 per share for at least 10 consecutive business days. NeuroOne is actively monitoring its stock price and exploring options to address the deficiency. If the company fails to meet the requirement within the given timeframe, it may be subject to delisting but could appeal the decision or seek additional time to comply.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.